LIFE | tickerfilter.com

Fundamental analysis

33%

Profitability 35%

Dept financing 24%

Liquidity 49%

Performance 30%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

0 0%

1 Month

0 0%

3 Months

-6.81%

6 Months

-18.18%

1 Year

-76.55%

2 Year

-50.46%

Key data

Stock price

$0.79

P/E Ratio

N/A

DAY RANGE

$0.78 - $0.81

EPS

-$0.80

52 WEEK RANGE

$0.64 - $7.29

52 WEEK CHANGE

-$77.16

MARKET CAP

0.000

YIELD

N/A

SHARES OUTSTANDING

98.051 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-01-2025

BETA

0.21

PUBLIC FLOAT

AVERAGE 10 VOLUME

N/A

AVERAGE 30 VOLUME

N/A

Company detail

CEO: Sanjay S. Shukla
Region: US
Website: atyrpharma.com
Employees: 53
IPO year: 2008

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trials for treatment of other interstitial lung diseases (ILDs) The company was incorporated in 2005 and is headquartered in San Diego, California.

LIFE - Atyr Pharma Inc